New asthma shot depemokimab tested in chinese volunteers
NCT ID NCT05140200
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single shot of depemokimab, a biologic drug for asthma, in 20 healthy Chinese adults. Researchers measured how the drug moves through the body and checked for side effects. The goal was to gather safety and dosing information for future studies in people with asthma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Depemokimab (a biologic drug given as a shot)
- What this could lead to
- If successful, this could help determine the right dose of depemokimab for Chinese patients with asthma, potentially leading to better symptom control.
- What could go wrong
- This is a very early Phase 1 study with only 20 healthy people, not asthma patients. It focuses on safety and drug levels, not on treating the disease. Many drugs fail in later trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Hangzhou, 310006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?